Novel Microbial-Based Immunotherapy Approach for Crohn's Disease
Simon Sutcliffe, Hal Gunn, Shirin Kalyan(University of British Columbia), Remo Panaccione(University of Calgary), Mark Bazett, Gillian Vandermeirsch, Boyko Kabakchiev(Mount Sinai Hospital), Richard N. Fedorak(University of Alberta), John K. Marshall(McMaster University), Jenny M. H. Chen, Dermot McGovern(Salford Royal NHS Foundation Trust), Andrew J. Coldman(Unknown), Rashieda Gluck, Momir Bosiljcic, Brian Bressler(University of British Columbia), Jim Pankovich, David W. Mullins(Wake Forest University), Darby Thompson(Simon Fraser University), Jeffrey Axler, Julie K. Jang(University of Southern California)
Cited by 9
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k